Chinese Skullcap

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: inflammation immunity stress

Research Overview

Research on Chinese skullcap (Scutellaria baicalensis; SB, Huang-Qin) has been most extensive in preclinical models, focusing on its major flavonoids—baicalin, baicalein, wogonin, and wogonoside—and on mechanistic endpoints such as oxidative stress, inflammation, apoptosis, and cell-signaling modulation. A large body of in vitro and animal work has examined anticancer activity across many tumor types (often emphasizing pathway regulation and potential synergy with standard chemotherapies), as well as broad “organ-protective” or antidotal effects against chemical toxicants, natural toxins, and physical hazards affecting organs including liver, kidney, heart, lung, and CNS. More targeted disease-model studies are also emerging, such as testosterone-induced benign prostatic hyperplasia (BPH) in rats (with outcomes related to androgen signaling and 5α-reductase/DHT) and polycystic ovary syndrome (PCOS) in rats (with emphasis on ferroptosis-related mechanisms and mitochondrial/oxidative pathways). Some work also explores antimicrobial activity of botanical medicines in contexts such as persistent Lyme disease symptoms, though the excerpted evidence is incomplete and primarily experimental.

The strongest evidence supported by these abstracts is that SB extracts and isolated flavonoids consistently demonstrate antioxidant and anti-inflammatory effects in controlled preclinical settings, frequently accompanied by reduced lipid peroxidation and modulation of apoptosis-related markers. In animal models, these mechanistic effects translate into measurable improvements in disease-relevant phenotypes (e.g., reduced ovarian oxidative stress and pathology in PCOS models; reduced prostate growth and androgen-related markers in BPH models). For oncology, the evidence base is broad but remains largely preclinical; wogonin in particular is repeatedly reported to inhibit cancer-related pathways and to enhance efficacy and reduce toxicity when combined with chemotherapeutics in experimental systems, supporting plausibility but not yet establishing clinical benefit.

Key gaps are the scarcity of high-quality human clinical trials and standardized preparations/dosing, which limits conclusions about efficacy, safety, and comparative effectiveness in real-world patients. Priority areas for further research include randomized controlled trials in specific indications suggested by animal data (e.g., BPH, PCOS-related reproductive outcomes, adjunctive oncology use), rigorous pharmacokinetic and bioavailability studies for major flavonoids, and systematic evaluation of herb–drug interactions and adverse events (including surveillance via case reports and pharmacoepidemiology). Additional work is also needed to clarify whether reported benefits in infectious or post-infectious syndromes reflect direct antimicrobial activity versus immunomodulatory effects, and to identify which constituents and molecular targets are most clinically relevant.

1. What conditions has Chinese Skullcap been studied for?

  • Cancers (primarily preclinical): Wogonin (a root flavonoid) has been studied across many cancer types in vitro and in vivo, including bladder, breast, cholangiocarcinoma, cervical, colorectal, gallbladder, gastric, glioblastoma, head and neck, hepatic, leukemia, lung, lymphoma, melanoma, multiple myeloma, neuroblastoma, osteosarcoma, ovarian, pancreatic, prostate, and renal cancers.

  • Polycystic ovary syndrome (PCOS): Baicalein was studied in a rat model of PCOS, including effects on ovarian dysfunction and pregnancy/placental outcomes.

  • Benign prostatic hyperplasia (BPH): Chinese skullcap root extract (SRE) was studied in testosterone-induced BPH rats, compared with finasteride.

  • Toxicant/organ injury models (mostly preclinical): Reviews summarize many in vitro/in vivo studies where total extract, baicalin, and baicalein were tested for protection against chemical toxicants and natural/physical hazards affecting organs such as brain/CNS, heart, liver, kidneys, lung.

  • Osteoarthritis symptom management (related product): Flavocoxid (a mixed extract containing baicalin plus catechin from black catechu) was evaluated in controlled clinical trials and postmarketing data for knee osteoarthritis versus naproxen.

  • Lyme disease (in vitro antimicrobial screening): One abstract describes investigation of antimicrobial effects of botanical medicines for persisting Lyme symptoms; details/results are truncated in the provided text.

  • Liver safety/toxicity: Case reports describe cholestasis/hepatitis linked to a supplement containing Chinese skullcap; another small human observational study assessed liver function tests before/after long-term skullcap root supplementation.

2. Does it work in treating those conditions? Summarize the evidence.

  • Cancer: Evidence in the abstracts is preclinical. The wogonin review reports “numerous in vitro and in vivo studies” showing anticancer activity across many tumor types and notes that combining wogonin with chemotherapeutic drugs may improve efficacy and lower toxicity. However, it explicitly states that human trials are warranted and that further high-quality studies are needed to establish clinical efficacy.

  • PCOS: In a rat PCOS model, baicalein reduced ovarian oxidative stress and pathology, decreased lipid peroxidation and chronic inflammation, and modulated mitochondrial function and ferroptosis-related markers; pregnancy/placental analyses suggested reversal of certain PCOS-associated changes after baicalein. This is promising but remains animal evidence, not proof of benefit in humans.

  • BPH: In testosterone-induced BPH rats, skullcap root extract (100–200 mg/kg/day) reduced prostate growth and lowered serum DHT and 5α-reductase levels, reduced AR and PCNA expression, and shifted Bax/Bcl-2 balance toward apoptosis. The abstract states effects were “more prevalent” than finasteride in that model. This is animal evidence; it does not establish effectiveness in men with BPH.

  • Protection from toxicants/organ injury: Two narrative reviews summarize large numbers of in vitro/in vivo studies (e.g., 221 studies from 1995–2021 in one review) suggesting protective effects against diverse toxic exposures via antioxidant/anti-inflammatory/anti-apoptotic mechanisms. Both emphasize that high-quality clinical evidence is scarce, limiting conclusions for real-world prevention/treatment.

  • Osteoarthritis (flavocoxid): Controlled clinical trials and postmarketing data cited in the abstract indicate flavocoxid was as effective as naproxen for knee osteoarthritis symptoms and had a better upper GI/renal/respiratory safety profile than naproxen. Important limitation: this is not skullcap alone; it is a combination product (baicalin + catechin) with a specific mechanism (COX-1/COX-2 peroxidase and 5-LOX inhibition).

  • Lyme disease: The provided abstract is incomplete; it indicates an investigation of antimicrobial effects of botanicals but does not provide outcomes here, so effectiveness cannot be assessed from the supplied text.

3. What health benefits does it have?

  • Anti-inflammatory and antioxidant effects (mechanistic/preclinical): Reviews attribute many protective effects of skullcap extract, baicalin, and baicalein to increased antioxidant enzymes and glutathione, inhibition of lipid peroxidation, reduction of inflammatory cytokines, and suppression of apoptosis pathways in toxicant/organ injury models.

  • Potential anticancer activity (preclinical): Wogonin is reported to regulate multiple cell signaling pathways across many cancer models; combination with chemotherapy is described as potentially improving efficacy and lowering toxicity (again, based on preclinical evidence in the abstract).

  • Potential reproductive/metabolic benefits in PCOS models (animal): Baicalein improved ovarian oxidative stress, inflammation, lipid peroxidation, and ferroptosis-related changes in a rat PCOS model, with additional placental gene-expression analyses suggesting effects on ferroptosis-negative regulation signatures.

  • Potential androgen/BPH-related benefits (animal): Skullcap root extract reduced DHT/5α-reductase and androgen receptor–related markers and improved histologic/pathologic features in a rat BPH model.

  • Potential symptom benefit in osteoarthritis (clinical, but combination product): Flavocoxid (containing baicalin) showed clinical efficacy comparable to naproxen for knee osteoarthritis symptoms in controlled trials cited in the abstract.

4. Does it have any downsides or side effects?

  • Rare but clinically significant liver injury has been reported: Case reports describe cholestasis and hepatitis in a patient taking an arthritis supplement containing Chinese skullcap (and black catechu), with improvement after stopping and recurrence upon rechallenge; biopsy was consistent with acute drug-induced liver injury. Another case report similarly attributes drug-induced liver injury to a “Move Free” product containing Chinese skullcap.

  • Causality is uncertain in some reports due to multi-ingredient supplements: One abstract notes NIH guidance that Scutellaria “has been implicated in rare instances of clinically apparent liver injury,” but also states that in published case reports, patients were concurrently taking at least one other supplement with an established association with hepatic dysfunction—making attribution to skullcap alone difficult.

  • Small human liver-function study suggests no signal—within its limits: In 17 adults taking 1335 mg/day dried root for an average of 444 days, ALT/AST/ALP/bilirubin did not change significantly and no clinical hepatic dysfunction occurred. Limitations include small sample size, lack of a control group, and limited ability to detect rare idiosyncratic liver injury.

  • Product quality and combinations may affect risk: The hepatotoxicity cases involved a multi-ingredient supplement; the abstracts do not resolve whether risk is due to skullcap itself, interactions, adulteration, or another ingredient.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (e.g., effects by genotype, metabolizer status, or specific variants affecting response or toxicity) for Chinese skullcap, wogonin, baicalein, or baicalin.

  • No direct evidence in the supplied text linking skullcap’s benefits or liver-injury risk to specific genetic variants.

  • Practical implication: Based on these abstracts alone, no genotype-based recommendations (beneficial or harmful) can be made.

References

  1. Wogonin and its analogs for the prevention and treatment of cancer: A systematic review.
    Kishore Banik, Elina Khatoon, Choudhary Harsha, Varsha Rana, Dey Parama, Krishan Kumar Thakur, Anupam Bishayee, Ajaikumar B Kunnumakkara (2022) - Phytotherapy research : PTR
  2. Baicalein improves the symptoms of polycystic ovary syndrome by mitigating oxidative stress and ferroptosis in the ovary and gravid placenta.
    Ying-Ying Li, Yi-Qiu Peng, Yu-Xi Yang, Ting-Juan Shi, Rui-Xia Liu, Ying-Yi Luan, Cheng-Hong Yin (2024) - Phytomedicine : international journal of phytotherapy and phytopharmacology
  3. Scutellaria baicalensis and its constituents baicalin and baicalein as antidotes or protective agents against chemical toxicities: a comprehensive review.
    Ali Ahmadi, Zoha Mortazavi, Soghra Mehri, Hossein Hosseinzadeh (2022) - Naunyn-Schmiedeberg's archives of pharmacology
  4. Protective and therapeutic effects of Scutellaria baicalensis and its main active ingredients baicalin and baicalein against natural toxicities and physical hazards: a review of mechanisms.
    Ali Ahmadi, Zoha Mortazavi, Soghra Mehri, Hossein Hosseinzadeh (2022) - Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
  5. Evaluation of Natural and Botanical Medicines for Activity Against Growing and Non-growing Forms of
    Jie Feng, Jacob Leone, Sunjya Schweig, Ying Zhang (2020) - Frontiers in medicine
  6. Chinese Skullcap (Scutellaria baicalensis Georgi) inhibits inflammation and proliferation on benign prostatic hyperplasia in rats.
    Bo-Ram Jin, Kyung-Sook Chung, Hyo-Jung Kim, Hyo-Jin An (2019) - Journal of ethnopharmacology
  7. Herbal hepatoxicity from Chinese skullcap: A case report.
    Leslie Yang, Andrew Aronsohn, John Hart, Donald Jensen (2012) - World journal of hepatology
  8. Flavocoxid, a nutraceutical approach to blunt inflammatory conditions.
    Alessandra Bitto, Francesco Squadrito, Natasha Irrera, Gabriele Pizzino, Giovanni Pallio, Anna Mecchio, Federica Galfo, Domenica Altavilla (2014) - Mediators of inflammation
  9. Polyphenols of Chinese skullcap roots: from chemical profiles to anticancer effects.
    Lingchong Wang, Dapeng Zhang, Ning Wang, Sha Li, Hor-Yue Tan, Yibin Feng (2019) - RSC advances
  10. The effect of supplementation with Scutellaria baicalensis on hepatic function.
    Basant K Puri, Nikita White, Jean A Monro (2019) - Medical hypotheses
  11. Chinese skullcap in move free arthritis supplement causes drug induced liver injury and pulmonary infiltrates.
    Renumathy Dhanasekaran, Victoria Owens, William Sanchez (2013) - Case reports in hepatology
  12. The Flavonoid Baicalein Negatively Regulates Progesterone Target Genes in the Uterus
    Kailiang Li, Djeneba Diakite, Julia Austin, Jung-Ho Lee, Daniel D Lantvit, Brian T Murphy, Joanna E Burdette (2022) - Journal of natural products
  13. Improving cachectic symptoms and immune strength of tumour-bearing mice in chemotherapy by a combination of Scutellaria baicalensis and Qing-Shu-Yi-Qi-Tang.
    Hang Wang, Yi-Lin Chan, Tsung-Lin Li, Chang-Jer Wu (2012) - European journal of cancer (Oxford, England : 1990)
  14. Baicalin and baicalein against myocardial ischemia-reperfusion injury: A review of the current documents.
    Reza Nasiri, Reza Arefnezhad, Kimia Baniasad, Seyed Ali Hosseini, Ahmadreza Samandari Jeshari, Mostafa Miri, Arezoo Lotfi, Mozhan Sadat Ghaemi, Ehsan Amini-Salehi, Hossein Fatemian, Fatemeh Rezaei-Tazangi, Prashant Kesharwani, Marziye Ranjbar Tavakoli, Amirhossein Sahebkar (2025) - Tissue & cell
  15. Effects of a
    Fiona Dodd, Ramon Weishaupt, Philipp K M Katumba, Rian Elcoate, Emma Wightman (2025) - Journal of psychopharmacology (Oxford, England)
  16. Scutellaria baicalensis and Lonicera japonica: An In-Depth Look at Herbal Interventions Against Oxidative Stress in Non-Ruminant Animals.
    Vetriselvi Sampath, Yu Jin Baek, In Ho Kim (2025) - Veterinary sciences


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!